Avalo Therapeutics (AVTX)

• Market cap: $371M
• 1 day: -8.39%
• 5 days: 18.5%
• 1 month: -6.01%
• 3 months: 2.26%
• 6 months: 16.21%
• Year to date: -4.41%
• 1 year: 182.47%
• 5 years: -99.81%
• 10 years: -99.85%
• Sector: Healthcare
• Industry: Biotechnology

About: Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

Employees: 33